Premium
Magnetic resonance imaging of esophageal squamous cell carcinoma using magnetite particles coated with anti‐epidermal growth factor receptor antibody
Author(s) -
Suwa Tatsushi,
Ozawa Soji,
Ueda Masakazu,
Ando Nobutoshi,
Kitajima Masaki
Publication year - 1998
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/(sici)1097-0215(19980209)75:4<626::aid-ijc22>3.0.co;2-5
Subject(s) - epidermal growth factor receptor , epidermal growth factor , in vivo , monoclonal antibody , pathology , magnetic resonance imaging , cell culture , magnetite , cancer research , cell , receptor , biophysics , materials science , chemistry , antibody , biology , medicine , immunology , biochemistry , radiology , genetics , microbiology and biotechnology , metallurgy
A highly specific and effective magnetic resonance imaging (MRI) contrast agent was prepared by coating super‐paramagnetite particles with monoclonal antibodies (MAbs) directed against epidermal growth factor receptors (EGFRs), which are over‐expressed in esophageal squamous cell carcinoma. The preparation maintained both the immuno‐reactivity of the MAbs and the full relaxing capability of the magnetite particles. The particles of this EGFR‐specific contrast agent are 13.2 ± 1.9 nm in size, and thus, it is assumed that they are smaller than capillary pores and, hence, able to escape scavenging by reticulo‐endothelial system cells. The EGFR‐specific T2‐relaxing ability of this contrast agent was ascertained first in vitro, using the EGFR‐expressing cell line TE8 and the EGFR‐deficient cell line H69. The results in athymic rats bearing TE8 or H69 tumors revealed that the agent has EGFR‐specific MRI contrast capacity in vivo. The electron‐microscopic findings in TE8 tumor‐bearing rats revealed that the magnetite particles had been taken up by their lysosomes. In conclusion, immuno‐specific MRI using magnetite particles coated with MAbs against EGFR appears to be useful in the diagnosis of squamous cell carcinoma of the esophagus. Int. J. Cancer 75:626–634, 1998. © 1998 Wiley‐Liss, Inc.